journal article·2021-12-10

Polysaccharide Nanogels for the Delivery of Gemcitabine Hydrochloride

Havva Rezaei Rudmianeh, Mostafa Shourian, Reza Ansari, Fateme Ghanbari Pirbasti, S Mohsen Asghari

ACS Applied Polymer Materials· Volume 3· Issue 12
Publisher page

Abstract

The clinical application of gemcitabine is limited by hydrophilicity and low plasma half-life. Herein, we developed a chitosan-based nanogel to provide controlled release of gemcitabine and relieve its hydrophilicity. Moreover, the chitosan nanogel is decorated with an alginate polyanion for pH-dependent and more controlled drug release. The effect of different variables on the polyelectrolyte reaction was evaluated using the Box–Benkehen design. The optimum formulation was determined based on higher encapsulation efficiency and loading capacity using HPLC analysis. In the light of the results, this synthesized nanogel has a diameter of around 150 nm and a polydispersity index of 0.344 and provides an acidic pH-dependent release profile. As a result of retaining the ability of cellular uptake, nanogel-loaded gemcitabine led to the cell cycle and apoptosis induction in MCF-7 breast cancer cells, followed by a considerably decreased half-maximal inhibitory concentration (IC50) of cell proliferation compared to free gemcitabine. Based on these results, the chitosan–alginate nanogel can be applied as a pH-dependent platform for the more controlled release behavior of gemcitabine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Faculty of Sciences, University of Guilan, Rasht 4199613776, Iran

Department of Biology, Faculty of Sciences, University of Guilan, Rasht 4199613776, Iran

Institute of Biochemistry and Biophysics, University of Tehran, P.O. Box 131451384, Tehran 1417614411, Iran

References (48)

Show source-provided references
1. American Cancer Society Breast Cancer Facts & Figures 2019-2020; American Cancer Society, Inc.: Atlanta, 2019; pp 1–44.
2. 10.1517/14796694.1.1.710.1517/14796694.1.1.7 ↗
3. 10.1007/s00280-016-3003-010.1007/s00280-016-3003-0 ↗
4. 10.1016/j.apsb.2019.08.00310.1016/j.apsb.2019.08.003 ↗
5. 10.1039/D1TB00628B10.1039/D1TB00628B ↗
6. 10.1016/j.addr.2009.07.01910.1016/j.addr.2009.07.019 ↗
7. 10.15171/apb.2017.06410.15171/apb.2017.064 ↗
8. 10.1039/C4RA05066E10.1039/C4RA05066E ↗
9. 10.1039/C1CS15239D10.1039/C1CS15239D ↗
10. 10.1016/j.carbpol.2011.04.01110.1016/j.carbpol.2011.04.011 ↗
11. 10.1016/j.carbpol.2020.11612610.1016/j.carbpol.2020.116126 ↗
12. 10.1021/bm201231x10.1021/bm201231x ↗
13. 10.1021/bm101044h10.1021/bm101044h ↗
14. 10.2217/nnm-2018-000410.2217/nnm-2018-0004 ↗
15. 10.1016/j.ijbiomac.2019.01.06510.1016/j.ijbiomac.2019.01.065 ↗
16. 10.1038/s41467-018-05261-x10.1038/s41467-018-05261-x ↗
17. 10.1002/pi.597010.1002/pi.5970 ↗
18. 10.5301/jabfm.500027810.5301/jabfm.5000278 ↗
19. 10.3390/ijms2103087310.3390/ijms21030873 ↗
20. 10.4314/tjpr.v12i2.1910.4314/tjpr.v12i2.19 ↗
21. 10.1038/s41467-020-15889-310.1038/s41467-020-15889-3 ↗
22. 10.1039/c2ra20702h10.1039/c2ra20702h ↗
23. 10.1038/s41598-018-23064-410.1038/s41598-018-23064-4 ↗
24. United States Pharmacopeial Convention · 2018
25. 10.1016/j.eurpolymj.2018.02.03110.1016/j.eurpolymj.2018.02.031 ↗
26. 10.2478/s11532-013-0360-y10.2478/s11532-013-0360-y ↗
27. 10.3390/ma1109152210.3390/ma11091522 ↗
28. 10.3390/nano1107185010.3390/nano11071850 ↗
29. 10.1021/jf900563a10.1021/jf900563a ↗
30. 10.1080/02726351.2010.50413310.1080/02726351.2010.504133 ↗
31. 10.1080/21691401.2018.156145710.1080/21691401.2018.1561457 ↗
32. 10.1002/ese3.81710.1002/ese3.817 ↗
33. 10.1039/C6RA07934B10.1039/C6RA07934B ↗
34. 10.1080/01496395.2018.148984510.1080/01496395.2018.1489845 ↗
35. 10.1007/s40005-014-0122-710.1007/s40005-014-0122-7 ↗
36. 10.3390/molecules2424456610.3390/molecules24244566 ↗
37. 10.1590/S0100-4670200400020000910.1590/S0100-46702004000200009 ↗
38. Stoica R. · J. Optoelectron. Adv. Mater. · 2013 · 15 · 893
39. 10.1016/j.tca.2006.03.00310.1016/j.tca.2006.03.003 ↗
40. 10.4103/0250-474X.5603310.4103/0250-474X.56033 ↗
41. 10.3390/polym1206132610.3390/polym12061326 ↗
42. 10.1080/02652048.2019.160484610.1080/02652048.2019.1604846 ↗
43. 10.1016/j.ijpharm.2020.11943510.1016/j.ijpharm.2020.119435 ↗
44. 10.1016/j.ijpharm.2012.08.00810.1016/j.ijpharm.2012.08.008 ↗
45. 10.1093/nsr/nwx06210.1093/nsr/nwx062 ↗
46. 10.1111/jcmm.1311010.1111/jcmm.13110 ↗
47. 10.1111/jmi.1213310.1111/jmi.12133 ↗
48. 10.1021/cr100316610.1021/cr1003166 ↗